LLY

729.83

-1.21%↓

JNJ

175.39

-0.94%↓

ABBV

206.2

-1.33%↓

UNH

301.19

-0.76%↓

AZN

79.85

-0.15%↓

LLY

729.83

-1.21%↓

JNJ

175.39

-0.94%↓

ABBV

206.2

-1.33%↓

UNH

301.19

-0.76%↓

AZN

79.85

-0.15%↓

LLY

729.83

-1.21%↓

JNJ

175.39

-0.94%↓

ABBV

206.2

-1.33%↓

UNH

301.19

-0.76%↓

AZN

79.85

-0.15%↓

LLY

729.83

-1.21%↓

JNJ

175.39

-0.94%↓

ABBV

206.2

-1.33%↓

UNH

301.19

-0.76%↓

AZN

79.85

-0.15%↓

LLY

729.83

-1.21%↓

JNJ

175.39

-0.94%↓

ABBV

206.2

-1.33%↓

UNH

301.19

-0.76%↓

AZN

79.85

-0.15%↓

Search

Recursion Pharmaceuticals Inc

Abrir

SetorSaúde

4.86

Visão Geral

Variação de preço das ações

24h

Atual

Mín

4.83

Máximo

5

Indicadores-chave

By Trading Economics

Rendimento

31M

-172M

Vendas

4.4M

19M

Margem de lucro

-899.843

Funcionários

800

EBITDA

44M

-148M

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

+21.33% upside

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-418M

2.1B

Abertura anterior

4.86

Fecho anterior

4.86

Sentimento de Notícias

By Acuity

50%

50%

172 / 372 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Recursion Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

27 de ago. de 2025, 22:51 UTC

Ganhos

Wesfarmers Plans Special Payout to Shareholders as Annual Net Profit Rises 14%

27 de ago. de 2025, 23:57 UTC

Ganhos

Trip.com Group 1H Rev $4.01B

27 de ago. de 2025, 23:57 UTC

Ganhos

Trip.com Group 1H Adj EPS $1.84

27 de ago. de 2025, 23:57 UTC

Ganhos

Trip.com Group 1H EPS $1.82

27 de ago. de 2025, 23:50 UTC

Conversa de Mercado

Nikkei May Decline Amid Caution Over Tariff Impact, Chip Demand -- Market Talk

27 de ago. de 2025, 23:39 UTC

Ganhos

Correction to Nvidia Earnings Article -- WSJ

27 de ago. de 2025, 22:59 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

27 de ago. de 2025, 22:59 UTC

Conversa de Mercado

HP CEO Sees Strong Back-to-School Spending on PCs -- Market Talk

27 de ago. de 2025, 22:58 UTC

Ganhos

South32 Records Significant Items of $71 Million Tied to Worsley, Mozal

27 de ago. de 2025, 22:57 UTC

Ganhos

South32 FY Free Cash Flow $192 Million

27 de ago. de 2025, 22:56 UTC

Ganhos

South32 FY Total Capital Expenditure $1.35 Billion

27 de ago. de 2025, 22:56 UTC

Ganhos

South32 FY Capital Expenditure $963 Million, Excluding EAIs

27 de ago. de 2025, 22:55 UTC

Ganhos

South32 Net Cash $123 Million at June 30

27 de ago. de 2025, 22:54 UTC

Ganhos

South32: Focused on Maintaining Strong Operating Momentum

27 de ago. de 2025, 22:53 UTC

Ganhos

South32: $144 Million Remains to be Returned to Shareholders Under Program

27 de ago. de 2025, 22:53 UTC

Ganhos

South32 Extends Capital Management Program for 12 Months

27 de ago. de 2025, 22:52 UTC

Ganhos

South32 FY Underlying Ebitda $1.93 Billion, Up 7% On-Year

27 de ago. de 2025, 22:51 UTC

Ganhos

South32 FY Revenue $5.78 Billion, Up 17% On-Year

27 de ago. de 2025, 22:51 UTC

Ganhos

South32 FY Underlying Earnings $666 Million, Up 75% On-Year

27 de ago. de 2025, 22:50 UTC

Ganhos

South32 to Pay Final Dividend of 2.6 U.S. Cents/Share

27 de ago. de 2025, 22:50 UTC

Ganhos

South32 FY Net Profit $213 Million Vs $203 Million Loss Year Earlier

27 de ago. de 2025, 22:45 UTC

Ganhos

Sandfire Resources Expects FY26 Matsa Capital Expenditure of $148 Million

27 de ago. de 2025, 22:44 UTC

Ganhos

Sandfire Resources Expects FY26 Motheo Unit Cost of $44/Ton of Ore Processed

27 de ago. de 2025, 22:44 UTC

Ganhos

Sandfire Resources Expects FY26 Motheo Capital Expenditure of $82 Million

27 de ago. de 2025, 22:43 UTC

Ganhos

Sandfire Resources Expects FY26 Matsa Unit Cost of $86/Ton of Ore Processed

27 de ago. de 2025, 22:43 UTC

Ganhos

Nvidia Breaks Sales Record Despite Chinese Trade Hiccups -- 5th Update

27 de ago. de 2025, 22:42 UTC

Ganhos

Sandfire Resources Expects FY26 Motheo Copper Eq Output to Rise 3% to 61,000 Tons

27 de ago. de 2025, 22:42 UTC

Ganhos

Sandfire Resources Expects FY26 Matsa Copper Eq Output to Rise 2% to 96,000 Tons

27 de ago. de 2025, 22:40 UTC

Ganhos

Sandfire Resources Net Debt $123 Million at June 30

27 de ago. de 2025, 22:40 UTC

Ganhos

Sandfire Resources FY Underlying Ebitda $527.7 Million

Comparação entre Pares

Variação de preço

Recursion Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

21.33% parte superior

Previsão para 12 meses

Média 5.86 USD  21.33%

Máximo 8 USD

Mínimo 3 USD

Com base em 6 analistas de Wall Street que oferecem metas de preço de 12 meses para Recursion Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

6 ratings

1

Comprar

5

Manter

0

Vender

Pontuação Técnica

By Trading Central

4.15 / 4.75Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

172 / 372 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.